본문 바로가기
KERD
논문KCI 등재후보

MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician

민필기|Richard C. Jin, MD|Stephen Y. Chan, MD
대한고혈압학회 (The Korean Society of Hypertension)|2013.03|Clinical Hypertension|제19권 제1호|pp. 1-16

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Pulmonary hypertensionMicroRNAsAnoxiaVascular diseases

초록

Since the first descriptions of their active functions more than ten years ago, small non-coding RNA species termed microRNA (miRNA) have emerged as essential regulators in a broad range of adaptive and maladaptive cellular processes. With an exceptionally rapid pace of discovery in this field, the dysregulation of many individual miRNAs has been implicated in the development and progression of various cardiovascular diseases. MiRNA are also expected to play crucial regulatory roles in the progression of pulmonary vascular diseases such as pulmonary hypertension (PH), yet direct insights in this field are only just emerging. This review will provide an overview of pulmonary hypertension and its molecular mechanisms, tailored for both basic scientists studying pulmonary vascular biology and physicians who manage PH in their clinical practice. We will describe the pathobiology of pulmonary hypertension and mechanisms of action of miRNA relevant to this disease. Moreover, we will summarize the potential roles of miRNA as biomarkers and therapeutic targets as well as future strategies for defining the cooperative actions of these powerful effectors in pulmonary vascular disease.

Abstract

Since the first descriptions of their active functions more than ten years ago, small non-coding RNA species termed microRNA (miRNA) have emerged as essential regulators in a broad range of adaptive and maladaptive cellular processes. With an exceptionally rapid pace of discovery in this field, the dysregulation of many individual miRNAs has been implicated in the development and progression of various cardiovascular diseases. MiRNA are also expected to play crucial regulatory roles in the progression of pulmonary vascular diseases such as pulmonary hypertension (PH), yet direct insights in this field are only just emerging. This review will provide an overview of pulmonary hypertension and its molecular mechanisms, tailored for both basic scientists studying pulmonary vascular biology and physicians who manage PH in their clinical practice. We will describe the pathobiology of pulmonary hypertension and mechanisms of action of miRNA relevant to this disease. Moreover, we will summarize the potential roles of miRNA as biomarkers and therapeutic targets as well as future strategies for defining the cooperative actions of these powerful effectors in pulmonary vascular disease.

참고문헌 (75)

  1. Alexander RP, "Annotating non-coding regions of the genome", Nat Rev Genet, 11, pp.559~571 (2010)
  2. Mercer TR, "Long non-coding RNAs : insights into functions", Nat Rev Genet, 10, pp.155~159 (2009)
  3. Esteller M, "Non-coding RNAs in human disease", Nat Rev Genet, 12, pp.861~874 (2011)
  4. Lewis BP, "Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets", Cell, 120, pp.15~20 (2005)
  5. Friedman RC, "Most mammalian mRNAs are conserved targets of microRNAs", Genome Res, 19, pp.92~105 (2009)
  6. Hammond SM, "Argonaute2, a link between genetic and biochemical analyses of RNAi", Science, 293, pp.1146~1150 (2001)
  7. Bartel DP, "MicroRNAs : target recognition and regulatory functions", Cell, 136, pp.215~233 (2009)
  8. Brodersen P, "Revisiting the principles of microRNA target recognition and mode of action", Nat Rev Mol Cell Biol, 10, pp.141~148 (2009)
  9. Lewis BP, "Prediction of mammalian microRNA targets", Cell, 115, pp.787~798 (2003)
  10. Doench JG, "siRNAs can function as miRNAs", Genes Dev, 17, pp.438~442 (2003)
  11. Filipowicz W, "Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?", Nat Rev Genet, 9, pp.102~114 (2008)
  12. Carthew RW, "Origins and mechanisms of miRNAs and siRNAs", Cell, 136, pp.642~655 (2009)
  13. Liu N, "MicroRNA regulatory networks in cardiovascular development", Dev Cell, 18, pp.510~525 (2010)
  14. Small EM, "Pervasive roles of microRNAs in cardiovascular biology", Nature, 469, pp.336~342 (2011)
  15. Abdellatif M, "Differential expression of microRNAs in different disease states", Circ Res, 110, pp.638~650 (2012)
  16. Urbich C, "Role of microRNAs in vascular diseases, inflammation, and angiogenesis", Cardiovasc Res, 79, pp.581~588 (2008)
  17. White K, "Holding our breath : the emerging and anticipated roles of microRNA in pulmonary hypertension", Pulm Circ, 2, pp.278~290 (2012)
  18. McLaughlin VV, "Pulmonary arterial hypertension", Curr Probl Cardiol, 36, pp.461~517 (2011)
  19. Schermuly RT, "Mechanisms of disease : pulmonary arterial hypertension", Nat Rev Cardiol, 8, pp.443~455 (2011)
  20. Simonneau G, "Updated clinical classification of pulmonary hypertension", J Am Coll Cardiol, 54(1 Suppl), pp.S43~S54 (2009)
  21. Lourenco AP, "Current pathophysiological concepts and management of pulmonary hypertension", Int J Cardiol, 155, pp.350~361 (2012)
  22. Morrell NW, "Cellular and molecular basis of pulmonary arterial hypertension", J Am Coll Cardiol, 54(1 Suppl), pp.S20~S31 (2009)
  23. Archer SL, "Basic science of pulmonary arterial hypertension for clinicians : new concepts and experimental therapies", Circulation, 121, pp.2045~2066 (2010)
  24. Tuder RM, "Pathology of pulmonary arterial hypertension", Semin Respir Crit Care Med, 30, pp.376~385 (2009)
  25. Jeffery TK, "Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension", Prog Cardiovasc Dis, 45, pp.173~202 (2002)
  26. Budhiraja R, "Endothelial dysfunction in pulmonary hypertension", Circulation, 109, pp.159~165 (2004)
  27. Frid MG, "Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte", macrophage lineage, 2006, pp.168, 659~669
  28. Zhao YD, "Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease", Circ Res, 96, pp.442~450 (2005)
  29. International PPH Consortium, "Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension", Nat Genet, 26, pp.81~84 (2000)
  30. Newman JH, "Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred", N Engl J Med, 345, pp.319~324 (2001)
  31. Eddahibi S, "Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease", Circulation, 108, pp.1839~1844 (2003)
  32. Archer SL, "Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension : a basis for excessive cell proliferation and a new therapeutic target", Circulation, 121, pp.2661~2671 (2010)
  33. Farber HW, "Pulmonary arterial hypertension", N Engl J Med, 351, pp.1655~1665 (2004)
  34. Chan SY, "Pathogenic mechanisms of pulmonary arterial hypertension", J Mol Cell Cardiol, 44, pp.14~30 (2008)
  35. Chan SY, "MicroRNA-210 : a unique and pleiotropic hypoxamir", Cell Cycle, 9, pp.1072~1083 (2010)
  36. Wang V, "Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells", Cancer Res, 65, pp.3299~3306 (2005)
  37. Maynard MA, "Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma", FASEB J, 19, pp.1396~1406 (2005)
  38. Weidemann A, "Biology of HIF-1alpha", Cell Death Differ, 15, pp.621~627 (2008)
  39. Adams JM, "HIF-1 : a key mediator in hypoxia", Acta Physiol Hung, 96, pp.19~28 (2009)
  40. Shimoda LA, "HIF and the lung : role of hypoxia-inducible factors in pulmonary development and disease", Am J Respir Crit Care Med, 183, pp.152~156 (2011)
  41. Parikh VN, "MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension : results of a network bioinformatics approach", Circulation, 125, pp.1520~1532 (2012)
  42. Caruso P, "Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline", Arterioscler Thromb Vasc Biol, 30, pp.716~723 (2010)
  43. Yang S, "miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling", Am J Physiol Lung Cell Mol Physiol, 302, pp.L521~L529 (2012)
  44. Courboulin A, "Role for miR-204 in human pulmonary arterial hypertension", J Exp Med, pp.535~548 (2011)
  45. Bockmeyer CL, "Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression", J Heart Lung Transplant, 31, pp.764~772 (2012)
  46. Brock M, "Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17", 92 pathway, 2009, pp.104, 1184~1191
  47. Pullamsetti SS, "Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension", Am J Respir Crit Care Med, 185, pp.409~419 (2012)
  48. Brock M, "AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension", Eur Heart J, 26 (2012)
  49. Caruso P, "A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples", Circ Res, 111, pp.290~300 (2012)
  50. Guo L, "The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C", Hypertension, 59, pp.1006~1013 (2012)
  51. Kim J, "An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension", Nat Med, 19, pp.74~82 (2013)
  52. Mitchell PS, "Circulating microRNAs as stable blood-based markers for cancer detection", Proc Natl Acad Sci U S A, 105, pp.10513~10518 (2008)
  53. Lawrie CH, "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", Br J Haematol, 141, pp.672~675 (2008)
  54. Chen X, "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases", Cell Res, 18, pp.997~1006 (2008)
  55. Zernecke A, "Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection", Sci Signal, 2, pp.ra81~ (2009)
  56. Valadi H, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells", Nat Cell Biol, 9, pp.654~659 (2007)
  57. Arroyo JD, "Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma", Proc Natl Acad Sci U S A, 108, pp.5003~5008 (2011)
  58. Vickers KC, "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins", Nat Cell Biol, 13, pp.423~433 (2011)
  59. Kuwabara Y, "Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage", Circ Cardiovasc Genet, 4, pp.446~454 (2011)
  60. Rhodes CJ, "Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension", Am J Respir Crit Care Med, pp.294~302 (2013)
  61. Zhang Y, "Secreted monocytic miR-150 enhances targeted endothelial cell migration", Mol Cell, 39, pp.133~144 (2010)
  62. Pegtel DM, "Functional delivery of viral miRNAs via exosomes", Proc Natl Acad Sci U S A, 107, pp.6328~6333 (2010)
  63. Mittelbrunn M, "Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells", Nat Commun, 2, pp.282~ (2011)
  64. Fichtlscherer S, "Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?", Arterioscler Thromb Vasc Biol, 31, pp.2383~2390 (2011)
  65. Xu J, "Circulating microRNAs: novel biomarkers for cardiovascular diseases", J Mol Med (Berl), 90, pp.865~875 (2012)
  66. Creemers EE, "Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?", Circ Res, 110, pp.483~495 (2012)
  67. Fabani MM, "Efficient inhibition of miR-155 function in vivo by peptide nucleic acids", Nucleic Acids Res, 38, pp.4466~4475 (2010)
  68. Lennox KA, "Chemical modification and design of anti-miRNA oligonucleotides", Gene Ther, 18, pp.1111~1120 (2011)
  69. Montgomery RL, "Therapeutic advances in MicroRNA targeting", J Cardiovasc Pharmacol, 57, pp.1~7 (2011)
  70. Krutzfeldt J, "Silencing of microRNAs in vivo with ‘antagomirs’", Nature, 438, pp.685~689 (2005)
  71. Care A, "MicroRNA-133 controls cardiac hypertrophy", Nat Med, pp.613~618 (2007)
  72. Thum T, "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts", Nature, 456, pp.980~984 (2008)
  73. Ma L, "Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model", Nat Biotechnol, 28, pp.341~347 (2010)
  74. Babar IA, "Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma", Proc Natl Acad Sci U S A, 109, pp.E1695~E1704 (2012)
  75. Cheng CJ, "Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing", Mol Pharm, 9, pp.1481~1488 (2012)

관련 논문AI추천

Therapeutic implications of microRNAs in pulmonary arterial hypertension강혜수, 김종민, 이아람, 장우철, 최지혜, Danielle McLean생화학분자생물학회 · BMB Reports2014 · 제47권 제6호MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology김종민생화학분자생물학회 · BMB Reports2018 · 제51권 제2호miR-15b induced by platelet-derived growth factor signaling is required for vascular smooth muscle cell proliferation강하라, 김성환생화학분자생물학회 · BMB Reports2013 · 제46권 제11호MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease하대유대한면역학회 · Immune Network2011 · 제11권 제3호Hypoxia-induced miR-1260b regulates vascular smooth muscle cell proliferation by targeting GDF11강하라, Minhyeong Seong생화학분자생물학회 · BMB Reports2020 · 제53권 제4호Crosstalk between BMP signaling and KCNK3 in phenotypic switching of pulmonary vascular smooth muscle cells서원희, Hayoung Jeong, Koung Li Kim, Min-Ju Kim, Yanghee Choi, Yeongju Yeo생화학분자생물학회 · BMB Reports2022 · 제55권 제11호

이 간행물의 다른 논문 (3건)

Renal Sodium Transporters and Water Channels김혜영pp. 17-22Influence of PD 123319 (AT2-Receptor Antagonist) on Catecholamine Secretion in the Perfused Rat Adrenal MedullaBhandary Bidur, 최미성, 서영환, 홍순표, Dong-Yoon Limpp. 23-38Middle Aortic Syndrome with Superior Mesenteric and Bilateral Renal Artery Involvement: Unusual Type of Aortic CoarctationJongSeon Parkpp. 39-43
원문 보기